Cemiplimab for advanced cutaneous squamous cell

featured image
Therapeutic Areas: Skin Cancer
Year: 2017

Cemiplimab is an intravenous drug under development for advanced cSCC. It acts on specific proteins
on immune cells, allowing the defence system of the body to inhibit the growth of the cancer cells.
For patients who develop advanced cSCC, there are limited treatment options available. If licensed,
cemiplimab may offer a new licenced treatment option for patients with advanced cSCC.